TITLE

BIOLINERX LICENSES PEPTIDE FOR INFLAMMATORY DISEASES

PUB. DATE
May 2007
SOURCE
Worldwide Biotech;May2007, Vol. 19 Issue 5, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports on the worldwide exclusive license agreement signed by BioLineRx Ltd., a drug development company in Israel, concerning a peptide for the treatment of inflammatory diseases, with Yissum Research Development Company of the Hebrew University of Jerusalem and Ramot at Tel Aviv University Ltd. The peptide called BL-4020 can serve as an inflammatory agent in diseases like allergic asthma and colitis.
ACCESSION #
24795580

 

Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;3/22/2007, Vol. 18 Issue 56, p2 

    The article offers news briefs on the pharmaceutical industry. Two products, the AV002 intermediate-acting, non-depolarizing neuromuscular blocking compound and a reversal agent, from Cornell University were licensed by Avera Pharmaceuticals Inc. A global license agreement has been signed by...

  • Yissum & Vaxan sign agreement for development of silver nanoparticles for Conductive Inks.  // Paintindia;Feb2011, Vol. 61 Issue 2, p77 

    The article reports on a licensing and research agreement signed by Yissum Research Development Co. Ltd. and Korea-based Vaxan Steel Co. Ltd. to develop silver nanoparticles and silver-coated copper nanoparticles for conductive inks. The inks invented by Shlomo Magdassi, Alexander Kamyshny and...

  • Other News To Note.  // BioWorld Today;6/28/2011, Vol. 22 Issue 124, p6 

    This section offers news briefs on the biotechnology industry as of June 28, 2011. Acorda Therapeutics Inc. is planning to transfer its headquarters to Ardsley, New York. A worldwide, exclusive license agreement has been signed by BioLineRx Ltd. with Yissum Research Development Co. Ltd. The U.S....

  • Safety study positive for cervical collar.  // Medical Device Daily;8/14/2007, Vol. 11 Issue 154, p10 

    The article reports that the Lubo Cervical Collar designed for use in trauma situations has demonstrated positive results in a safety study, according to Hadasit and Ramot at Tel Aviv University Ltd. The study was approved by the Institutional Review Board and was registered with the National...

  • Yissum Introduces a Novel Method for Treating Cancer Based on a Protein Encoded by HIV-1.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article provides information on a novel method for treating cancer based on Vif, a protein isolated from the Human Immunodeficiency Virus (HIV-1) by Yissum Research Development Co. Ltd. The scientists discovered a small peptide derived from the HIV-1 Vif protein, which inhibits DNA repair...

  • Licensing agreement on pain treatment.  // Medical Device Daily;5/29/2009, Vol. 13 Issue 102, p2 

    The article reports on a licensing agreement between Z-Cube and Yissum Research Development, the technology transfer company of the Hebrew University of Jerusalem. Under the agreement, the latter will create and commercialize a nanotechnology drug-delivery system for pain invented by Elka...

  • Removal Authority.  // Dispute Resolution Journal;Feb-Apr2011, Vol. 66 Issue 1, p90 

    The article discusses a court case over medical licensing rights dispute between appellant Infuturia Global Ltd. of the British Virgin Islands and Yissum Research and Development Co. of Israel. Infuturia has brought a case against Sequus Pharmaceuticals Inc. of California, Hebrew University of...

  • Agreements/contracts.  // Medical Device Daily;6/17/2009, Vol. 13 Issue 115, p3 

    The article reports on a license and development agreement signed by Nuvo Research with Mallinckrodt in 2009 involving its topical non-steroidal anti-inflammatory drug candidates, Pennsaid and Pennsaid Plus. Under the terms of the agreement, Nuvo will receive an up-front, non-refundable payment...

  • Isis, Kite Pharma Rocket Higher On Deals. AMY REEVES // Investors Business Daily;1/6/2015, pB06 

    Biotech Isis Pharmaceuticals leapt 10% to a new high above 68 Monday after it signed a licensing deal with Johnson & Johnson worth up to $835 million.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics